Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Metastatic Neuroendocrine-like Prostate Cancer
NCT03179410Phase 2Completed
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in neuroendocrine prostate cancer (NEPC). Primary endpoint: Number of Participants With Overall Response as Determined by iRECIST at 6 months. Started Feb 2018; status: completed.
02
Drugs
avelumab
03
Conditions
neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT03179410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179410.